ORG 33628 and ORG 31710 to Control Vaginal Bleeding in Progestin-Only Contraceptive Regimens

ABSTRACT

ORG 31710 and ORG 33628 were used in studies aiming to control vaginal bleeding in combination with progestagen-only contraception in primates. Preclinical evidence in monkeys with ORG 31710 has shown that a monthly supplementary administration to a progestagen-only contraceptive improves cycle control, probably as a result of a local endometrial effect (i.e., blocking of the progesterone receptor). In clinical trials ORG 31710 appeared to be effective for inducing vaginal bleeding after single-dose administration in the luteal phase of a normal cycle and for improving vaginal bleeding patterns of subjects using the 75 μg desogestrel progestagen-only pill (POP). Under POP treatment, ORG 31710 induced monthly bleeding and completely reduced intermittent (or breakthrough) bleedings, albeit for a limited number of days (± 10 days); thereafter, the incidence of spot bleedings returned to average levels with a POP, until the next monthly ORG 31710 administration. The temporary character of the effect was not predicted on the basis of the monkey studies, in which the improved bleeding pattern lasted a full cycle. Similar clinical results have been obtained with ORG 33628 both as administered in the luteal phase of the normal cycle and as given once (and twice) every 28 days in combination with the 75 μg desogestrel POP. Again, the improvement of the (POP-) bleeding pattern was not considered effective enough. In another approach, a continuous combined (daily) treatment of a progestagen (desogestrel) and the compound ORG 33628 was evaluated. It was hypothesized that if properly balanced, the progestagen would provide sustained ovulation inhibition, while the antagonistic activity of ORG 33628 would provide prevention of intermittent vaginal bleedings without antagonizing the inhibition of ovulation. This hypothesis is supported by the observation (from previous studies) that the antagonistic activity is higher at the level of the endometrium than at the level of the hypothalamus/pituitary. The continuous combined concept was studied in a single-center, double-blind, randomized trial of ORG 33628 at three different dosages in combination with the 75 μg desogestrel POP administered to healthy female volunteers. Effects on vaginal bleeding, endometrium, and ovarian function were evaluated. Vaginal bleeding was reduced with increasing doses of ORG 33628, but the inhibition of ovulation appeared to be compromised at the same time. In summary, the available studies suggest that there may be a progestagen/progesterone receptor-antagonist combination that provides the desired cycle control without compromising the inhibition of ovulation, but the ideal regimen or ratio has yet to be found.

KEYWORDS

Progesterone antagonists (PAs) - selective progesterone receptor modulators (SPRMs) - progestin-only contraception - cycle control - vaginal bleeding - progestagens - ORG 33628 - ORG 31710

REFERENCES

• 1 Kloosterboer H J, Deckers G H, Schoonen W GEJ. Pharmacology of two new very selective antiprogestagens: Org 31710 and Org 33628.  Hum Reprod. 1994;  9(suppl 1) 47-52
• 2 Kloosterboer H J, Deckers G H, Schoonen W G et al.. Preclinical experience with two selective progesterone receptor modulators on breast and endometrium.  Steroids. 2000;  65 733-740
• 3 Schoonen W GEJ, Vermeulen G J, Deckers G H, Verbost P M, Kloosterboer H J. Antiprogestins: their mechanism of action and the consequences for compound selection by in vitro and in vivo studies.  Curr Top Ster Res. 1999;  2 15-54
• 4 Kloosterboer H J, Deckers G H, de Gooyer M E, Dijkema R, Orlemans E OM, Schoonen W GEJ. Pharmacological properties of a new selective antiprogestagen: Org 33628.  Ann N Y Acad Sci. 1995;  761 192-201
• 5 Snedecor G W, Cochran W G. Statistical Methods, 6th ed. Ames, IA; The Iowa State University Press 1967: 248
• 6 Belsey E M, Machin D, d'Arcangues C. The analysis of vaginal bleeding patterns induced by fertility regulating methods.  Contraception. 1986;  34 253-260
• 7 Van Heusden A M, Killick S R, Coelingh Bennink H JT, Fauser B CJM. Single monthly administration of the anti-progestagen Org 31710 in users of the 75 μg desogestrel progestagen-only pill: effects on pituitary-ovarian activity.  Hum Reprod. 2000;  15 629-636
• 8 McCann M F, Potter L S. Progestin-only oral contraception: a comprehensive review.  Contraception. 1994;  50(6 suppl 1) S9-S195
• 9 Rice C F, Killick S R, Dieben T, CoelinghBennink H. A comparison of the inhibition of ovulation achieved by desogestrel 75 μg and levonorgestrel 30 μg daily.  Hum Reprod. 1999;  14 982-985
• 10 Korver T, Klipping C, Heger-Mahn D, Van Osta G. Maintenance of consistent ovulation inhibition with the 75 mcg desogestrel-only contraceptive pill Cerazette after scheduled 12-hour delays in tablet intake.  Contraception. 2005;  71 8-13
• 11 Edwards RG, Beard HK, Findlay JK Menstrual disorders and progestin contraception. Hum Reprod 1996 11(suppl 2)
• 12 Grow D R, Reece M T. The role of selective oestrogen receptor modulators in the treatment of endometrial bleeding in women using long-acting progestin contraception.  Hum Reprod. 2000;  15(suppl 3) 30-38
• 13 Alvarez-Sanchez F, Brache V, Thevenin F, Cochon L, Faundes A. Hormonal treatment for bleeding irregularities in Norplant implant users.  Am J Obstet Gynecol. 1996;  174 919-922
• 14 Datey S, Gaur L N, Saxena B N. Vaginal bleeding patterns of women using different contraceptive methods (implants, injectables, IUDs, oral pills): an Indian experience.  Contraception. 1995;  51 155-165
• 15 Dorflinger L. Medical contraindications and issues for consideration in the use of once-a-month injectable contraceptives.  Contraception. 1994;  49 455-468
• 16 Williams R F, Kloosterboer H J, Verbost P M, Hodgen G D. Once monthly antiprogestin controls menstrual bleeding during progestin-only contraception in primates.  J Soc Gynecol Invest. 1997;  4 221 (Abst)
• 17 Healy D L, Baulieu E E, Hodgen G D. Induction of menstruation by an anti-progesterone (RU 486) in monkeys.  Fertil Steril. 1983;  40 253-257
• 18 Gemzell Danielsson K, van Heusden A M, Killick S R et al.. Improving cycle control in progestin-only contraceptive pill users by intermittent treatment with a new antiprogestin.  Hum Reprod. 2002;  17 2588-2593
• 19 Heikinheimo O, Gordon K, Williams R F, Hodgen G D. Inhibition of ovulation by progestin (agonists vs antagonists): preliminary evidence for different sites and mechanisms of action.  Contraception. 1996;  53 55-64
• 20 Landgren B-M, Balogh A, Shin M W, Lindberg M, Diczfalusy E. Hormonal effects of the 300 μg norethisterone (NET) minipill. 2. Daily gonadotrophin levels in 43 subjects during a pretreatment cycle and during the second month of NET administration.  Contraception. 1979;  20 585-605
• 21 Kim-Björklund T, Landgren B-M, Hamberger L. Is the contraceptive effect of norethisterone mainly peripheral or central?.  Contraception. 1992;  45 57-66
• 22 Lähteenmäki P LA, Lähteenmäki P. Concentration-dependent mechanisms of ovulation inhibition by the progestin ST-1435.  Fertil Steril. 1985;  44 20-24
• 23 Dericks-Tan J SE, Gudacker V, Taubert H D. Influence of oral contraceptives on integrated secretion of gonadotropins.  Contraception. 1992;  46 369-377
• 24 Obruca A, Korver T, Huber J, Killick S R, Landgren B-M, Struijs M J. Ovarian function during and after treatment with the new progestagen Org 30659.  Fertil Steril. 2001;  76 108-115